Impact of COVID-19 pandemic on prostate cancer outcomes at an uro-oncology referral center

Autor(es)

Guilherme Miranda Andrade ^[1] ; Lucas Sesconetto ^[2] ; Rafael Benjamim Rosa da Silva ^[3] ; Gabriela Guimarães Rodrigues dos Santos ^[4] ; Paulo Priante Kayano ^[5] ; Willy Baccaglini ^[6] ; Murilo Borges Bezerra ^[7] ; Bianca Bianco ^[8] ; Gustavo Caserta Lemos ^[9] ; Arie Carneiro ^[10]

Afiliação do(s) autor(es)

^[1] Hospital Israelita Albert Einstein. Departamento de Urologia - Brasil

^[2] Hospital Israelita Albert Einstein. Departamento de Urologia - Brasil

^[3] Hospital Israelita Albert Einstein. Departamento de Urologia - Brasil

^[4] Faculdade Israelita de Ciências da Saúde Albert Einstein - Brasil

^[5] Hospital Israelita Albert Einstein. Departamento de Urologia - Brasil

^[6] Hospital Israelita Albert Einstein. Departamento de Urologia - Brasil

^[7] Faculdade Israelita de Ciências da Saúde Albert Einstein - Brasil

^[8] Hospital Israelita Albert Einstein. Departamento de Urologia - Brasil

^[9] Hospital Israelita Albert Einstein. Departamento de Urologia - Brasil

^[10] Hospital Israelita Albert Einstein. Departamento de Urologia - Brasil

• Tipo de documento: Artigo Científico
• Fonte: INTERNATIONAL BRAZ J UROL; v. 49, n. 2, p. 233-242, 2023-06-09.

Resumo

ABSTRACT Introduction To evaluate the possible effects of the coronavirus disease 2019 (COVID-19) pandemic on the oncologic results of patients with prostate cancer regarding clinical staging, presence of adverse pathological outcomes, and perioperative complications. Materials and methods This retrospective study included patients who underwent radical prostatectomy. The time between biopsy and surgery, staging tests, final histopathological evaluation after surgery, lymphadenectomy rate, postoperative complications, and prostatic specific antigen (PSA) levels (initial and 30 days after surgery) were analyzed and compared in a group of patients before and during the pandemic period. Results We included 226 patients: 88 in the pre-pandemic period and 138 during the pandemic period. There was no statistically significant difference in mean age, body mass index, ASA, pathological locally advanced disease, the proportion of patients who underwent lymphadenectomy, and ISUP grade in the biopsy between the groups. Positive surgical margins, prostatic extracapsular extension, and PSA levels at 30 days were also similar between the groups. The mean time between medical consultation and surgery was longer in the pandemic period than in the pre-pandemic (124 vs. 107 days, p<0.001), and the mean time between biopsy and medical consultation (69.5 days vs. 114 days, p<0.001) and between biopsy and surgery (198.5 days vs. 228 days, p=0.013) was shorter during the pandemic. The incidence of severe early and late perioperative complications was similar between the periods. Conclusions There was no delay between diagnosis and treatment at our institution during the COVID-19 pandemic period. No worsening of the prostate cancer features was observed. (AU)

• Processo FAPESP: 22/01458-0 - Efeitos da pandemia COVID-19 em pacientes submetidos a prostatectomia radical
• Beneficiário: Murilo Borges Bezerra
• Modalidade de apoio: Bolsas no Brasil - Iniciação Científica